IMUGENE LIMITED — AGM Information 2013

Nov 19, 2013

NEW THERAPEUTIC DIRECTIONS� Dr Nick Ede, Executive Director AGM PRESENTATION - 20 NOVEMBER 2013

New Therapeutic Directions – AGM November 2013

Imugene Limited� (ASX:IMU)�

Suite 1, 1233 High Street, Armadale VIC 3143

Dr Nick Ede Executive Director

m: +61 (0) 400 642 254 e: nede@imugene.com w: imugene.com�

New Therapeutic Directions – AGM November 2013

Forward looking statement�

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Imugene Limited’s control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this brochure include known and unknown risks. As actual results may differ materially to any assumptions made in this brochure, you are urged to view any forward looking statements contained in this brochure with caution. This presentation should not be relied on as a recommendation or forecast by Imugene Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

==> picture [131 x 43] intentionally omitted <==

Key Messages 2013 HIGHLIGHTS�

Rapid progress Committed in advancing to driving the technology � business� for immediate for the long term returns

Strategy for new innovation and new drug development on track

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013

New Therapeutic Directions – AGM November 2013

==> picture [131 x 43] intentionally omitted <==

50% Up to of the general population suffers from difficulty in swallowing tablets.

Oral medicine is the largest segment of pharmaceuticals yet there are few solutions for the Dysphagia (swallowing problems) market.

==> picture [131 x 43] intentionally omitted <==

1. Sastry et al Pharm Sci & Tech Today 3: 138-145, 2000 2. Seager J Pharma Pharmacol 50: 375-382, 1998 New Therapeutic Directions – AGM November 2013

LINGUET[TM ]

THE OPPORTUNITY�

Linguet™ is a platform Buccal Delivery System which uses PEG molecules to modulate transport across mucosal membranes resulting in:�

Research commissioned by Imugene indicated that people would try a meltlet or buccal delivery tablet:�

• If it is convenient and pleasant to take;

• If it didn’t leave a residue or aftertaste;

• If it dissolved in less than a minute;

• For vitamins such as D and B, pain medications and other RX medications; and

• If it was marketed by a well known brand.

==> picture [56 x 59] intentionally omitted <==

• Lower dose of drugs required, e.g. avoids loss of drug when passed through stomach;

• Reduction in drug side effects, e.g. stomach ulcers from pain drugs such as Voltaren® and Nurofen®;

• Protection of drugs in oral delivery, e.g. masks unpleasant taste of drugs such as Nurofen®;

• Improvement in patient compliance, e.g. no swallowing required;

• Extension of big pharma patent life, e.g. new drug formulation can be protected; and

• Platform extensions into Consumer Healthcare market with a new melt-inmouth (meltlet) proposition.

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013

Consumer Healthcare Opportunities NEARER TERM REVENUE DRIVERS�

In 2013, Imugene has extended its Linguet technology to the Consumer Healthcare Market with a ’ meltlet ’ for:

• Vitamins, Supplements and Nutraceuticals

• vitamins specifically vitamin D (development complete and currently being commercialised), minerals and herbal ranges;

• In November 2013, Imugene has entered into an R&D project with a Global Consumer Healthcare company and their TGA approved manufacturer (both unnamed for confidentiality and competition reasons);

• First right of refusal to exclusively license results and products created;

• Vitamins and supplements industry is big business in Australia, worth an estimated $1.5bn each year;

• The industry is growing at up to 12% annually.

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013

KEY MESSAGES�

• Linguet™ provides a solution and a point of difference nutraceutical and pharmaceutical companies

• Licensing of Linguet platform for vitamins and supplements in progress ( Q4 2013 exploratory R&D project initiated)

• Key Opinion Leaders providing strong support for Therapeutic vitamin D (buccal delivery) development

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013

==> picture [645 x 133] intentionally omitted <==

==> picture [645 x 68] intentionally omitted <==

ACQUISITION OF BIOLIFE SCIENCE QLD LTD� A Phase II Ready Cancer Immunotherapy Company

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013

THE TARGET – HER-2/neu�

• HER-2/neu belongs to the epidermal growth factor receptor family;

• Tumor-associated antigen. Low/no antigen expression on normal tissue;

• Overexpressed antigen on various tumors; e.g. gastric, breast, ovarian, & pancreatic cancers;

• .

• Associated with aggressively growing tumors with poor prognosis

==> picture [246 x 196] intentionally omitted <==

==> picture [259 x 196] intentionally omitted <==

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013

HOW HERCEPTIN® WORKS�

==> picture [191 x 51] intentionally omitted <==

==> picture [580 x 306] intentionally omitted <==

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013

THE PRODUCT – how HER-Vaxx works?�

==> picture [483 x 173] intentionally omitted <==

• Rather than injecting a ready-made antibody like Herceptin®, HER-Vaxx activates a patient’s own immune system to produce its own HER2 antibodies

• The strategy is to induce a polyclonal antibody response with similar anti-tumor properties as Herceptin® → Effectively turns the patient’s body into a “Herceptin® factory”�

• Like Herceptin®, HER-Vaxx is directed against the HER-2 receptor. It consists of several B-cell peptides derived from the extracellular domain of HER-2 (B-cell vaccine)

• No HLA (human leukocyte antigen) restriction! (advantage over T cell vaccine responses)

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013

BUSINESS STRATEGY - EXIT�

==> picture [669 x 246] intentionally omitted <==

“Cancer immunotherapies turn corner in race to mega blockbuster market” Fierce Biotech October 2013

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013

PRICED WELL BELOW PHASE II ASX PEERS�

==> picture [673 x 292] intentionally omitted <==

As of 15 October 2013� Source: Bloomberg�

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013

WHY IMUGENE?�

• Unlike many vaccine attempts, HER-Vaxx is directed against a validated target;�

• Successful Phase I results in metastatic breast cancer; excellent safety and toxicology profile;

• Potentially significant advantages over Herceptin® and Perjeta®;

• Her-Vaxx planned FDA Phase II trial is robust and Big Pharma orientated;

• Attractively priced and heavily discounted to Phase II peers.�

• In addition, Linguet™ technology close to revenues in 2014�

==> picture [131 x 43] intentionally omitted <==

New Therapeutic Directions – AGM November 2013